Prognostic value of response after upfront therapy for acute GVHD
about
Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.Steroid-Refractory Acute GVHD: Predictors and Outcomes.Plasma biomarkers of lower gastrointestinal and liver acute GVHD.Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.Have we improved in preventing and treating acute graft-versus-host disease?Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Treatment and management of graft-versus-host disease: improving response and survival.Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and deathSix-month freedom from treatment failure is an important end point for acute GVHD clinical trialsPentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.Assessing response of therapy for acute and chronic graft-versus-host disease.State-of-the-art acute and chronic GVHD treatment.Long-term follow-up of corticosteroid refractory acute GVHD treated with an Inolimomab-based algorithm: a single center experience.Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease.MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD.Prognosis of grade 3-4 acute GVHD continues to be dismal.Infusion of bone marrow derived multipotent mesenchymal stromal cells for the treatment of steroid-refractory acute graft-versus-host disease: a multicenter prospective study.
P2860
Q34093615-95A9940C-8F26-4925-A26C-B8B833B18AA1Q35550596-48005654-7B1A-4E06-BAFD-7DE34649C8D8Q35891657-7E49B43A-B8D1-47F5-9347-06D137EF1626Q35909700-DCF27723-7E29-458A-B0FB-9533B415826DQ36113205-1AFC8A27-F476-4FFA-9847-05FE0413DB93Q36203692-1100F10F-AA67-44DA-8C94-19DBC2ECB9F4Q36821646-04B1DC7E-ABE8-45DF-BD23-D0CDBACFF2C4Q37371836-99D5C1B6-2B77-42C2-A44C-97EDCD4908DAQ37552088-F398769C-C275-4F9F-ACCF-C022C4EC95E6Q37618997-F6C428BB-01B2-4264-92B5-BE46077C40DCQ37624271-533E45B9-3713-4BF2-A118-098EF614ABE8Q37696092-43E487D3-9679-43AC-B805-7BCBDFB1D1B9Q38078431-4757244A-35EF-40E5-888A-732D9FC8D579Q38416376-D38C60B6-E97D-4C1B-BDAE-0464F8D9D3ACQ42270601-6D425EC6-F249-42E9-9B31-EBFFDD4E99BCQ48146759-2FBC9968-620D-400C-B62F-6A129EB1CDAAQ48231285-06CE6EC7-BB64-4D39-BF51-980BBD250ED7Q52653321-698279AF-33AE-498E-AC2E-68AB3B008BF5Q53110668-959463FD-16F9-417A-AB7A-86E12972B35DQ55319551-27BE72DE-D95D-441B-8212-1C9A334AA6D1
P2860
Prognostic value of response after upfront therapy for acute GVHD
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prognostic value of response after upfront therapy for acute GVHD
@ast
Prognostic value of response after upfront therapy for acute GVHD
@en
type
label
Prognostic value of response after upfront therapy for acute GVHD
@ast
Prognostic value of response after upfront therapy for acute GVHD
@en
prefLabel
Prognostic value of response after upfront therapy for acute GVHD
@ast
Prognostic value of response after upfront therapy for acute GVHD
@en
P2093
P2860
P356
P1476
Prognostic value of response after upfront therapy for acute GVHD
@en
P2093
A M Alousi
D R Couriel
G-J Okoroji
R E Champlin
R M Saliba
P2860
P2888
P304
P356
10.1038/BMT.2011.41
P407
P577
2011-03-07T00:00:00Z
P5875
P6179
1022226549